<?xml version="1.0" encoding="UTF-8"?>
<p>The European Medicine Agency has reported clinical studies on the effects of 
 <italic>C. asiatica</italic> on chronic venous insufficiency (CVI), periodontitis, psoriasis, ulcer cicatrization, burn recovery, anxiety, and atherosclerosis. Clinical studies showed that 
 <italic>C. asiatica</italic> improves microcirculation and leg volume associated with decreased edema and symptoms. The safety profile of 
 <italic>C. asiatica</italic> extracts appears satisfactory and tolerable as it is emerging from clinical studies in patients affected by CVI and from its use in products on the market. Clinical trials have reported no drug-related serious adverse events. The recommended doses for non-toxic nature with no or infrequent adverse side effects are 60â€“180 mg daily. However, at a higher dose, there may be occasional burning pain or skin allergy following injection or topical application. In addition, gastric complaints and nausea have occasionally been reported following oral administration of 
 <italic>C. asiatica</italic> extract [
 <xref rid="B32-antibiotics-10-00457" ref-type="bibr">32</xref>,
 <xref rid="B110-antibiotics-10-00457" ref-type="bibr">110</xref>]. In general, there are no reasons for concerns relating to safety, and the tolerability of oral 
 <italic>C. asiatica</italic> preparations was good in all studies. No adverse events from pharmacovigilance data are known [
 <xref rid="B111-antibiotics-10-00457" ref-type="bibr">111</xref>].
</p>
